Research
Safe and effective platelet transfusion has been part of medical practice for a long time, and so is autologous (re-transfusion to the same person) platelet-rich Plasma (PRP). Our product combines the concepts of both in a practical, efficient and safe method to employ allogenic (from one person to another) platelet-derived growth factors to recipient after ensuring the safety of the product.
XelyoMax is protected by an international patent: Permanent research results in an innovative efficient and cutting-edge cell therapy.
Many studies and cases have proven that XelyoMax is not only an innovative, but most of all a very efficient, practical and safe method to employ allogeneic platelet-derived growth factors to a recipient. During the process we monitor and ensure the safety of our product while maintaining a standard growth factor concentration. We refined traditional PRP therapy with our new cutting-edge technology, which is how treatment is transformed from autologous to allogeneic. The result is clustered in XelyoMax, an easy-to-use, efficient and innovative treatment.
